Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I and Randomized Phase II Multicenter Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer

Trial Profile

A Phase I and Randomized Phase II Multicenter Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Feb 2019

At a glance

  • Drugs Cabozantinib (Primary) ; Docetaxel; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Feb 2019 Results of pooled analysis of phase 1/2 study assessing safety and efficacy of cabozantinib plus docetaxel and prednisone versus docetaxel and prednisone alone in metastatic castrate-resistant prostate cancer presented at the 2019 Genitourinary Cancers Symposium
    • 17 Jan 2019 Status changed from active, no longer recruiting to completed.
    • 15 Jun 2018 Planned End Date changed from 1 Jun 2018 to 1 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top